<DOC>
	<DOCNO>NCT00950911</DOCNO>
	<brief_summary>The purpose study describe safety tolerability denosumab administration measure adverse event , immunogenicity , safety laboratory parameter subject previously receive either zoledronic acid ( ZometaÂ® ) denosumab .</brief_summary>
	<brief_title>Open Label Extension SRE Studies United Kingdom Czech Republic Only</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subjects currently enrol study 20050103 , 20050136 , 20050244 Subjects must sign informed consent study specific procedure perform Developed sensitivity mammalian cell derive drug product 20050103 , 20050136 , 20050244 study Currently receive unapproved investigational product denosumab Subject pregnant breast feeding , plan become pregnant within 7 month end treatment Subject ( male female ) willing use 2 highly effective contraception treatment 7 month ( woman ) 10 month ( men ) end treatment Male subject pregnant partner willing use condom treatment additional 10 month end treatment Any disorder , opinion investigator , may compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Bone metastasis</keyword>
	<keyword>Hormone-refractory prostate cancer</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Denosumab</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>20050103</keyword>
	<keyword>20050136</keyword>
	<keyword>20050244</keyword>
	<keyword>Advanced cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Zoledronic acid</keyword>
</DOC>